Protocol No.: D6900C00003

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)
Principal Investigator
Pfaendler, Krista
Phase
III (Cancer Control)
Age Group
Adult
Applicable Disease Site
Gynecologic Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Jill Stone, LPN
Research Specialist
Phone: +1 304-634-4417

View on ClinicalTrials.gov